The most advanced clinical trial design is a phase 3, multicentre, randomised, double-blind, placebo-controlled study of AG-881 in subjects with residual or recurrent grade 2 glioma with an IDH1 or IDH2 mutation (Table 1) [178]. This evidence concerns the gene IDH2 and glioma.